Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 00:00:02 14/02/2026 +03			5-day change	1st Jan Change
121.41 ^USD	+1.82%		-0.43%	+15.34%

02-13	Merck Shares Rise After Deutsche Bank Upgrade	MT
02-13	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid January Consumer Price Inflation Report	MT

Global drugmakers rush to boost US presence as tariff threat looms

Published on 01/13/2026 at 03:52 pm +03

Reuters

Latest news about Merck & Co., Inc.

02-13	Merck Shares Rise After Deutsche Bank Upgrade	MT
02-13	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid January Consumer Price Inflation Report	MT
02-13	Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115	MT
02-13	Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115	MT
02-13	Merck & Co. Insider Sold Shares Worth $1,214,562, According to a Recent SEC Filing	MT
02-12	Argus Adjusts Price Target on Merck to $130 From $110, Maintains Buy Rating	MT
02-12	Merck Advances Treatment of Bladder and Kidney Cancers with New Data At 2026 ASCO GU Cancers Symposium	CI
02-11	Sector Update: Health Care Stocks Rise Late Afternoon	MT
02-11	Sector Update: Health Care Stocks Advance Wednesday Afternoon	MT
02-11	Sector Update: Health Care	MT
02-11	Daiwa Securities Adjusts PT on Merck & Co. to $120 From $86, Maintains Neutral Rating	MT
02-11	Merck Announces the U.S. Food and Drug Administration Approves KEYTRUDA (Pembrolizumab and Berahyaluronidase Alfa-Pmph) and KEYTRUDA QLEX	CI
02-11	Agilent's Ovarian Cancer Diagnostic Test Receives FDA Clearance	MT
02-11	Merck Says US FDA Approves Keytruda Combination in Platinum-Resistant Ovarian Cancer	MT
02-11	Merck & Co. Insider Sold Shares Worth $1,202,844, According to a Recent SEC Filing	MT

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (20%); - sale of animal health products (9.2%); - other (1.4%). Net sales are distributed geographically as follows: the United States (50.3%), Europe/Middle East/Africa (21.8%), Latin America (5.4%), China (8.6%), Japan (5.1%), Asia/Pacific (4.8%) and other (4%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

03-16 -

More about the company